<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Proteinuria in pregnancy: Diagnosis, differential diagnosis, and management of nephrotic syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Proteinuria in pregnancy: Diagnosis, differential diagnosis, and management of nephrotic syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Proteinuria in pregnancy: Diagnosis, differential diagnosis, and management of nephrotic syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ravi I Thadhani, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sharon E Maynard, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Clinicians caring for pregnant people need to understand how to identify proteinuria in pregnancy and determine the cause. Proteinuria is one of the cardinal features of preeclampsia  (<a class="graphic graphic_table graphicRef79977" href="/z/d/graphic/79977.html" rel="external">table 1</a>), a common and potentially severe complication of pregnancy. Proteinuria is also a sign of primary kidney disease or kidney disease secondary to systemic disorders, such as diabetes mellitus or hypertension. Adding to the complexity, 20 to 25 percent of pregnant people with chronic hypertension, diabetes mellitus, or chronic kidney disease develop superimposed preeclampsia [<a href="#rid1">1,2</a>]. </p><p>This topic will discuss diagnosis of proteinuria in pregnancy, differential diagnosis, and management of pregnant people with nephrotic syndrome. The evaluation of proteinuria in nonpregnant individuals and measurement of protein excretion are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3101.html" rel="external">"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults"</a>.)</p><p>Pregnancy issues in patients with kidney disease are also discussed separately:</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7205.html" rel="external">"Pregnancy and contraception in patients with nondialysis chronic kidney disease"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/7237.html" rel="external">"Acute kidney injury in pregnancy"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/117110.html" rel="external">"Pregnancy in patients on dialysis"</a>.)</p><p></p><p class="headingAnchor" id="H2880115876"><span class="h1">DIAGNOSIS/DEFINITION</span><span class="headingEndMark"> — </span>In pregnancy, urinary protein excretion normally increases substantially to 150 to 250 mg daily and is not considered abnormal until it exceeds 300 mg daily [<a href="#rid3">3</a>]. In many pregnant people, proteinuria appears to increase further during labor and delivery [<a href="#rid4">4</a>]. Abnormal proteinuria is similarly defined for singleton and multiple gestations, even though pregnant people with twin pregnancies have greater increases in urinary protein excretion than those with singleton pregnancies and may exceed 300 mg daily in the absence of any pathology [<a href="#rid5">5,6</a>]. By comparison, in nonpregnant individuals without kidney disease, normal urinary protein excretion is less than 150 mg daily and normal albumin excretion is than 30 mg daily [<a href="#rid7">7</a>].</p><p>Urinary protein excretion increases substantially during pregnancy due to a combination of increased glomerular filtration rate (GFR) and increased permeability of the glomerular basement membrane [<a href="#rid8">8</a>]. Additionally, tubular reabsorption of filtered protein is reduced in pregnancy, along with other nonelectrolytes, such as amino acids, glucose, and beta-microglobulin. Additional information on pregnancy-related changes in kidney function and the urinary tract can be found separately. (See  <a class="medical medical_review" href="/z/d/html/404.html" rel="external">"Maternal adaptations to pregnancy: Renal and urinary tract physiology"</a>.)</p><p class="headingAnchor" id="H1086498933"><span class="h1">MEASUREMENT</span></p><p class="headingAnchor" id="H3"><span class="h2">Semiquantitative (screening)</span><span class="headingEndMark"> — </span>The urinary dipstick is used to screen for proteinuria. </p><p>Standard urine dipstick testing should be performed on a fresh, clean voided, midstream urine specimen, obtained before pelvic examination to minimize the chance of contamination from vaginal secretions. The urinary dipstick for protein is a semi-quantitative colorimetric test that primarily detects albumin. Results range from negative to 4+, corresponding to the following estimates of protein excretion:</p><p class="bulletIndent1"><span class="glyph">●</span>Negative</p><p class="bulletIndent1"><span class="glyph">●</span>Trace – between 15 and 30 mg/dL</p><p class="bulletIndent1"><span class="glyph">●</span>1+ – between 30 and 100 mg/dL</p><p class="bulletIndent1"><span class="glyph">●</span>2+ – between 100 and 300 mg/dL</p><p class="bulletIndent1"><span class="glyph">●</span>3+ – between 300 and 1000 mg/dL</p><p class="bulletIndent1"><span class="glyph">●</span>4+ – &gt;1000 mg/dL</p><p></p><p>A positive reaction (1+) for protein develops at the threshold concentration of 30 mg/dL, which crudely corresponds to a 24-hour urinary protein excretion of 300 mg/day, depending on urine volume.</p><p>Although inexpensive and commonly used, the urinary dipstick has a high false-positive and false-negative rate when used to screen for abnormal proteinuria in pregnancy, especially at the 1+ level [<a href="#rid9">9,10</a>]. This is due primarily to variability in urine concentration (osmolality), which can substantially affect random urine protein concentration (ie, the dipstick result).</p><p>False-positive tests may occur in the presence of gross (macroscopic) blood in the urine, semen, very alkaline urine (pH &gt;7), quaternary ammonium compounds, detergents and disinfectants, drugs, radio-contrast agents, and concentrated urine (specific gravity &gt;1.030). Positive tests for protein due to blood in the urine seldom exceed 1+ by dipstick. </p><p>False negatives may occur with dilute urine (specific gravity &lt;1.010), high salt concentration, highly acidic urine, or nonalbumin proteinuria. False-negative urine dipstick proteinuria testing is most common in the third trimester of pregnancy, when the clinical findings of preeclampsia are most likely to manifest [<a href="#rid11">11</a>].</p><p>Because the urinary dipstick has low diagnostic accuracy for the detecting proteinuria in pregnancy, it is not recommended as a routine screening test for preeclampsia by the United States Preventive Services Task Force [<a href="#rid12">12</a>]. However, it is commonly performed and the detection of proteinuria at the level of 2+ or greater by urine dipstick may be used for the diagnosis of preeclampsia if quantitative methods are unavailable [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis", section on 'Screening and risk reduction'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Quantitative (diagnostic)</span><span class="headingEndMark"> — </span>Urinary protein can be measured as either albumin or total protein. There are three methods to quantify proteinuria: 24-hour urine collection, spot urine protein-to-creatinine ratio, and spot urine albumin-to-creatinine ratio. </p><p class="headingAnchor" id="H5"><span class="h3">24-hour urine collection</span><span class="headingEndMark"> — </span>The traditional method to quantify proteinuria requires a 24-hour urine collection to directly measure the daily total protein or albumin excretion. If urine and serum creatinine are also measured, the 24-hour urine collection creatinine clearance can provide an estimate of the glomerular filtration rate.</p><p>The 24-hour collection is begun at the usual time the patient awakens. At that time, the first void is discarded and the exact time noted. Subsequently, all urine voids are collected with the last void timed to finish the collection at exactly the same time the next morning. The time of the final urine specimen should vary by no more than 5 or 10 minutes from the time of starting the collection the previous morning. </p><p>An inexpensive basin urinal that fits into the toilet bowl facilitates collection for pouring into a bottle. The bottle(s) may be kept at normal room temperature for a day or two, but should be kept cool or refrigerated for longer periods of time. No preservatives are needed. (See  <a class="medical medical_patient" href="/z/d/html/2181.html" rel="external">"Patient education: Collection of a 24-hour urine specimen (Beyond the Basics)"</a>.)</p><p>Although generally considered the "gold standard" for diagnosis of proteinuria in both preeclampsia and kidney disease, the 24-hour urine protein excretion in pregnant people is frequently inaccurate due to under-collection or over-collection [<a href="#rid14">14</a>]. Thus, when interpreting the results of a 24-hour urine collection, it is critical to assess the adequacy of collection by quantifying the 24-hour urine creatinine excretion, which depends on muscle mass. In a complete collection, the 24-hour urine creatinine excretion will be between 15 and 20 mg/kg body weight, calculated using prepregnancy weight. Values substantially above or below this estimate suggest over- and under-collection, respectively, and should call into question the accuracy of the 24-hour urine protein result.</p><p>In addition to the high rate of inaccurate/incomplete collection, the 24-hour urine sample is cumbersome for ambulatory patients, and the laboratory result is not available for at least 24 hours while the collection is being completed and analyzed [<a href="#rid14">14</a>]. </p><p class="headingAnchor" id="H6"><span class="h3">Urine protein-to-creatinine ratio</span><span class="headingEndMark"> — </span>The spot urine protein-to-creatinine ratio (UPCR) has become the preferred method for the quantification of proteinuria in the nonpregnant population because of its high accuracy, reproducibility, and convenience when compared with timed urine collection [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/3101.html" rel="external">"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults"</a>.)</p><p>For preeclampsia diagnosis, proteinuria is defined as a 24-hour urine protein excretion &gt;300 mg, spot protein-to-creatinine ratio &gt;0.3 mg/mg (&gt;300 mg/g, or approximately &gt;30 mg/mmol), or ≥2+ on urinary dipstick if quantitative measurement is unavailable [<a href="#rid13">13</a>].</p><p>Some laboratories and international guidelines use UPCR in units of mg protein per mmol creatinine (mg/mmol). To convert mg/mmol to mg/g, multiply by 8.84. An UpToDate calculator is available for calculating the UPCR using spot urine protein and spot urine creatinine values (<a class="calc calc_professional" href="/z/d/html/13493.html" rel="external">calculator 1</a>).</p><p>Most studies evaluating UPCR to quantify proteinuria in pregnancy were performed in patients with suspected preeclampsia. In a 2020 meta-analysis, the UPCR was highly correlated with the 24-hour urine protein measurement [<a href="#rid16">16</a>], as it is in nonpregnant adults. A urine protein-to-creatinine ratio less than 30 mg/mmol (260 mg/g) had a high sensitivity (91 percent) and specificity (89 percent) for the diagnosis of proteinuria &gt;300 mg/day by 24-hour urine collection. Use of the UPCR has also been validated for baseline proteinuria quantification in early pregnancy [<a href="#rid17">17</a>].</p><p>However, many obstetricians still prefer use 24-hour urine collection to measure proteinuria in pregnancy.</p><p class="headingAnchor" id="H7"><span class="h3">Urine albumin-to-creatinine ratio</span><span class="headingEndMark"> — </span>The urine albumin-to-creatinine ratio (UACR), like the UPCR, is measured using a random "spot" urine specimen. (See  <a class="medical medical_review" href="/z/d/html/3101.html" rel="external">"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults"</a>.)</p><p>The UACR can be performed using an automated analyzer, allowing immediate point-of-care testing that could be utilized in an antenatal clinic. Like the UPCR, the UACR (using a threshold between 20 and 60 mg albumin/g creatinine) is strongly predictive of significant proteinuria (&gt;300 mg protein/day by 24-hour urine collection) in a high-risk obstetric population [<a href="#rid18">18,19</a>] and in patients with hypertensive pregnancies [<a href="#rid20">20,21</a>]. In one study, pregnant people with a spot UACR &gt;312 mg albumin/g creatinine measured at 17 to 20 weeks of gestation were at almost eightfold higher risk of subsequently developing preeclampsia (relative risk [RR] 7.8) compared with those with UACR &lt;312 mg albumin/g creatinine [<a href="#rid22">22</a>]. The UACR performs similarly to the UPCR with regard to prediction of adverse pregnancy outcomes [<a href="#rid23">23</a>]. </p><p>Some laboratories report UACR in units of mg albumin per mmol creatinine (mg/mmol). To convert mg/mmol to mg/g, multiply by 8.84.</p><p class="headingAnchor" id="H2862820"><span class="h3">8- or 12-hour collection</span><span class="headingEndMark"> — </span>Although not commonly used, measurement of protein in an 8-hour [<a href="#rid24">24</a>] or 12-hour [<a href="#rid25">25</a>] urine collection is a reasonable alternative to the 24-hour urine collection for quantification of proteinuria. In a systematic review including seven studies, &gt;150 mg of protein in a 12-hour collection was highly predictive of &gt;300 mg protein in a 24-hour collection (pooled sensitivity 92 percent [95% CI 86-96], specificity 99 percent [75-100]) [<a href="#rid25">25</a>]. Alternatively, the urine protein-to-creatinine ratio may be measured from an aliquot of urine taken from a 16- or 24-hour urine collection [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H8"><span class="h1">DIFFERENTIAL DIAGNOSIS OF PROTEINURIA</span><span class="headingEndMark"> — </span>For patients in whom proteinuria is the prominent finding, distinguishing between preeclampsia and other forms of kidney disease can be challenging. Initial assessment should include determination of the gestational age at onset and quantity of proteinuria. If the onset is after 20 weeks gestation, preeclampsia is likely  (<a class="graphic graphic_table graphicRef79977" href="/z/d/graphic/79977.html" rel="external">table 1</a>) (see  <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a>). If the onset is before 20 weeks gestation, primary or secondary kidney disease is likely  (<a class="graphic graphic_table graphicRef67810" href="/z/d/graphic/67810.html" rel="external">table 2</a>). </p><p class="headingAnchor" id="H727727757"><span class="h2">Kidney disease versus preeclampsia</span><span class="headingEndMark"> — </span>The distinction between kidney disease and preeclampsia is important because it affects prognosis and management. Primary or secondary kidney disease may require diagnostic testing (including kidney biopsy in some cases) and disease-specific therapy. In these patients, the usual aim is delivery at term. The definitive treatment for preeclampsia is delivery, which is typically performed preterm when severe features or fetal complications are present. (See  <a class="medical medical_review" href="/z/d/html/7205.html" rel="external">"Pregnancy and contraception in patients with nondialysis chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a>.)</p><p>When proteinuria is documented before the 20<sup>th</sup> week of gestation, underlying kidney disease is likely because preeclampsia rarely occurs before that time. Conversely, new-onset proteinuria after 20 weeks of gestation suggests preeclampsia. Approximately one-third of pregnant people who present with new proteinuria after 20 weeks of gestation eventually progress to preeclampsia [<a href="#rid27">27,28</a>], which may have severe features [<a href="#rid29">29</a>], and 25 percent of pregnant people with preeclampsia have proteinuria as their initial presenting sign [<a href="#rid30">30</a>]. In such cases, adverse pregnancy and neonatal outcomes are more common as compared with patients in whom hypertension was the first presenting sign of preeclampsia [<a href="#rid30">30,31</a>].</p><p>In preeclampsia, the degree of proteinuria is only weakly associated with adverse maternal and neonatal outcomes. Heavy proteinuria is not considered a severe feature of preeclampsia [<a href="#rid32">32-36</a>], although some studies report severe proteinuria (&gt;3 to 5 g/day) is associated with earlier gestational age at preeclampsia onset, earlier gestational age at delivery, and a higher incidence of fetal growth restriction as compared with mild proteinuria [<a href="#rid37">37,38</a>]. Proteinuria may be absent in preeclampsia: up to 10 percent of patients with preeclampsia and 20 percent of those with eclampsia have no proteinuria at the time of initial presentation [<a href="#rid39">39,40</a>]. Proteinuria is no longer required for the diagnosis of preeclampsia, according to American College of Obstetricians and Gynecologists guidelines, if severe features of the disease are present  (<a class="graphic graphic_table graphicRef79977" href="/z/d/graphic/79977.html" rel="external">table 1</a>) [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a>.)</p><p>Of course, de novo kidney disease (for example, lupus nephritis) can also occur later in pregnancy. Distinguishing between kidney disease and preeclampsia can be difficult in these cases, especially when information on protein excretion (and hypertension) in early pregnancy is unavailable. For this reason, it is useful to quantify protein excretion in early pregnancy in patients at risk for kidney disease (ie, patients with chronic hypertension, diabetes mellitus, and systemic lupus erythematosus). </p><p>The following algorithms and UpToDate topics are useful for evaluating patients suspected of having kidney disease  (<a class="graphic graphic_algorithm graphicRef113287" href="/z/d/graphic/113287.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef105740" href="/z/d/graphic/105740.html" rel="external">algorithm 2</a>). Of note, urinary tract dilation (eg, &gt;3 cm) on kidney ultrasound has been associated with proteinuria in pregnancy [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/102837.html" rel="external">"Chronic kidney disease (newly identified): Clinical presentation and diagnostic approach in adults"</a>.)</p><p>Measurement of soluble fms-like tyrosine kinase-1 (sFlt1) and placental growth factor (PlGF) may be helpful for the diagnosis of preeclampsia [<a href="#rid42">42,43</a>]. sFlt1 and PlGF are angiogenic factors secreted by the placenta and implicated in the pathogenesis of preeclampsia. The sFlt1:PlGF maternal serum assay is available in Europe and the United States. Although more studies are needed to validate its use, this serologic test may prove useful and cost-effective in distinguishing preeclampsia from other causes of proteinuria in pregnancy [<a href="#rid44">44,45</a>] and appears to be predictive of preeclampsia with severe features, adverse maternal outcomes, and adverse neonatal outcomes in patients with clinical suspicion of preeclampsia [<a href="#rid46">46-48</a>]. The sFlt1:PlGF ratio may be particularly helpful in distinguishing chronic kidney disease and preeclampsia [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/z/d/html/6760.html" rel="external">"Preeclampsia: Pathogenesis", section on 'sFlt-1, VEGF, PlGF'</a>.)</p><p>In some cases, the distinction between kidney disease and preeclampsia can only be made in retrospect, as clinical signs of preeclampsia generally resolve within 12 weeks after delivery [<a href="#rid50">50</a>], while proteinuria due to underlying kidney disease does not. However, resolution of proteinuria after preeclampsia, especially when severe features are present, can sometimes take much longer. In observational studies of patients with preeclampsia, it is common for proteinuria to persist for six months or longer after delivery [<a href="#rid51">51</a>]. Nevertheless, proteinuria (or hypertension) that persists longer than three months after delivery should prompt close follow-up and consideration of further evaluation and appropriate referral so that underlying renal disease or chronic hypertension is detected and treated expeditiously.</p><p class="headingAnchor" id="H1398709017"><span class="h2">Worsening kidney disease versus superimposed preeclampsia</span><span class="headingEndMark"> — </span>Preeclampsia is common in pregnant people with preexisting kidney disease and/or hypertension. Superimposed preeclampsia typically manifests as new or worsening hypertension, often with worsening proteinuria, after 20 weeks of gestation. A substantial (twofold or greater) increase in proteinuria may be a sign of impending preeclampsia [<a href="#rid52">52</a>]. Hematologic, neurologic, and hepatic complications  (<a class="graphic graphic_table graphicRef76975" href="/z/d/graphic/76975.html" rel="external">table 3</a>) and/or evidence of fetal compromise (including fetal growth restriction) may also point to a diagnosis of superimposed preeclampsia.</p><p>Alternatively, worsening proteinuria in a pregnant patient with kidney disease may reflect the effect of pregnancy on the underlying kidney disease. Patients with chronic kidney disease often have a twofold or greater increase in proteinuria in pregnancy [<a href="#rid53">53-55</a>].</p><p class="headingAnchor" id="H3362225950"><span class="h2">Nephrotic syndrome versus preeclampsia</span><span class="headingEndMark"> — </span>Nephrotic-range proteinuria (&gt;3 g/24 hours) is a sign of glomerular injury. Proteinuria less than 3 g/day is usually asymptomatic, while proteinuria &gt;3 g/day may cause the nephrotic syndrome, with edema and hypoalbuminemia. The serum albumin concentration decreases in normal pregnancy, so it has been suggested that the nephrotic syndrome in pregnancy can be diagnosed by the presence of proteinuria &gt;3 g/day and albumin below the lower limit of normal based on gestational age: &lt;3.1 g/dL in the first trimester, &lt;2.6 g/dL in the second trimester, and &lt;2.3 g/dl in the third trimester [<a href="#rid56">56,57</a>].</p><p>Preeclampsia is the most common cause of de novo nephrotic-range proteinuria in pregnancy. In a retrospective study of 104 patients with nephrotic-range proteinuria during pregnancy who were evaluated postnatally, the diagnosis was preeclampsia alone in 60 percent, superimposed preeclampsia in 9 percent, newly diagnosed kidney disease in 9 percent, worsening proteinuria due to preexisting kidney disease in 6 percent (no hypertension), and isolated gestational proteinuria in 1 percent [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/z/d/html/3084.html" rel="external">"Overview of heavy proteinuria and the nephrotic syndrome"</a>.)</p><p>Nephrotic range proteinuria during pregnancy due to primary glomerular disease is associated with a high risk of several adverse outcomes, including superimposed preeclampsia, acute kidney injury, preterm birth, low birth weight, and the need for neonatal intensive care [<a href="#rid59">59</a>]. Nevertheless, conservative management until delivery, particularly in patients who present in the third trimester, is often a reasonable management approach. When nephrotic syndrome presents early in pregnancy, and/or there is progressive decline in kidney function, timely treatment of the underlying kidney disease is often indicated. In such cases, the potential benefits of kidney biopsy may outweigh the risks. (See <a class="local">'Role of kidney biopsy in pregnancy'</a> below.)</p><p class="headingAnchor" id="H449434937"><span class="h1">ROLE OF KIDNEY BIOPSY IN PREGNANCY</span><span class="headingEndMark"> — </span>In clinical practice, kidney biopsy is rarely needed in pregnancy. A clinical diagnosis is often established based on the history, physical examination, and serologic testing for primary and secondary glomerular disease. When indicated, serologic testing should be performed for lupus nephritis (ie, antinuclear antibodies and anti-double stranded DNA antibody titers and complement levels), membranous nephropathy (anti-PLA2R antibody), and infections associated with glomerular diseases (eg, HIV and hepatitis C virus). The decision to perform kidney biopsy during pregnancy is based on several factors, including the gestational age, the severity of the kidney disease, and the suspected underlying diagnosis.</p><p>Data on the safety of renal biopsy during pregnancy are limited. The major complication is bleeding. In a systematic review of reports of kidney biopsies performed during pregnancy or postpartum, the risk of bleeding was higher when the biopsy was performed during pregnancy as compared with postpartum (7 percent [16/197] versus 1 percent [3/268]) [<a href="#rid60">60</a>]. All observed cases of major bleeding (ie, requiring blood transfusion) occurred in biopsies performed between 23 to 26 weeks of gestation, suggesting patients in this gestational age range may be particularly vulnerable to complications. Early in pregnancy, the benefit of a biopsy (accurate diagnosis and subsequent tailored management) is more likely to outweigh its risks. Later in gestation, the gravid uterus makes the standard prone position for biopsy difficult. In such cases, the biopsy can be performed with the patient in the lateral decubitus position or deferred until the patient has stabilized postpartum. </p><p><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> should be held for five to seven days prior to and one to two weeks following kidney biopsy to minimize the risk of bleeding. (See  <a class="medical medical_review" href="/z/d/html/3067.html" rel="external">"The kidney biopsy"</a>.)</p><p class="headingAnchor" id="H5992575"><span class="h1">MANAGEMENT OF NEPHROTIC SYNDROME IN PREGNANCY</span><span class="headingEndMark"> — </span>The management of nephrotic syndrome in pregnancy is based on expert opinion, as minimal data are available to support evidence-based practice. In nonpregnant patients with nephrotic syndrome, inhibitors of the renin-angiotensin aldosterone system (ie, angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists) are routinely used as nonspecific therapy to reduce proteinuria. These agents are contraindicated in pregnancy, due to well-documented teratogenicity, particularly in the second and third trimesters of pregnancy. (See  <a class="medical medical_review" href="/z/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppressive drugs</strong> — First-line therapy for nephrotic syndrome caused by glomerular disease frequently includes immunosuppressive agents. Immunosuppressive drugs generally considered safe for use in pregnancy include <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, glucocorticoids, and calcineurin inhibitors (eg, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>). <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> are teratogenic and should be avoided in pregnancy. <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> is generally avoided in pregnancy, though there are reports of its use without adverse fetal consequences [<a href="#rid61">61,62</a>]. There are inadequate data on the safety of <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">belimumab</a>, <a class="drug drug_general" data-topicid="130589" href="/z/d/drug information/130589.html" rel="external">voclosporin</a>, and <a class="drug drug_general" data-topicid="132266" href="/z/d/drug information/132266.html" rel="external">anifrolumab</a> in pregnancy, so these agents should also be avoided. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-dose </strong><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a><strong> </strong>—<strong> </strong>In pregnant patients with chronic kidney disease, low-dose aspirin starting before 16 weeks of gestation is recommended to reduce the risk of developing preeclampsia later in gestation. The use of aspirin for preeclampsia prevention is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6817.html" rel="external">"Preeclampsia: Prevention"</a> and  <a class="medical medical_review" href="/z/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Low-dose aspirin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of edema</strong> — Edema related to nephrotic syndrome in pregnancy can often be successfully managed without the use of diuretics. The dietary intake of sodium may be modestly limited. Graduated compression stockings and leg elevation are safe and often effective methods to facilitate resolution of edema.</p><p></p><p class="bulletIndent1">Diuretics are avoided, if possible, because of the theoretical risk that they may impair pregnancy-associated expansion of plasma volume. However, there is no clear evidence of adverse fetal effects, and loop diuretics may be safely used in pregnant people with severe, refractory edema [<a href="#rid63">63</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulation</strong> — Nephrotic syndrome is associated with an increased risk of deep venous thrombosis (DVT). Patients with severe nephrotic syndrome (particularly those with membranous nephropathy) and severe hypoalbuminemia who are not at high risk for bleeding may benefit from prophylactic anticoagulation (eg, with subcutaneous low molecular weight heparin). A suggested approach to prophylactic anticoagulation in pregnant people is presented in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome", section on 'Pregnant patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of hyperlipidemia</strong> — Statins are avoided in pregnancy because of limited and contradictory data suggesting an increased risk of congenital anomalies with first-trimester exposure. We suggest discontinuing statins in females taking them because of nephrotic syndrome and planning pregnancy, and then resuming the drugs after delivery/breast feeding. (See  <a class="medical medical_review" href="/z/d/html/4564.html" rel="external">"Statins: Actions, side effects, and administration", section on 'Risks in pregnancy and breastfeeding'</a>.)</p><p></p><p class="bulletIndent1">Bile acid sequestrants and fibrates have no established teratogenic effects and can be safely used in pregnancy to treat severe hyperlipidemia due to nephrotic syndrome.</p><p></p><p class="headingAnchor" id="H3510078203"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/109729.html" rel="external">"Society guideline links: Hypertensive disorders of pregnancy"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4420.html" rel="external">"Patient education: Protein in the urine (proteinuria) (Beyond the Basics)"</a>) </p><p></p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – In pregnancy, urinary protein excretion normally increases substantially to 150 to 250 mg daily. (See <a class="local">'Diagnosis/definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – Urine dipstick is routinely used to screen for proteinuria in pregnancy, but false-positive and false-negative results are common. It is most predictive of abnormal proteinuria if +2 or greater. Positive urine dipsticks should be followed up with a quantitative test. (See <a class="local">'Measurement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urine protein-to-creatinine ratio</strong> – The spot urine protein-to-creatinine ratio (UPCR; mg protein/mg creatinine) is an accurate, convenient, and relatively rapid method to quantify proteinuria in pregnancy. A UPCR greater than 0.3 mg/mg (30 mg/mmol) after 20 weeks gestation is one of the diagnostic criteria for preeclampsia  (<a class="graphic graphic_table graphicRef79977" href="/z/d/graphic/79977.html" rel="external">table 1</a>). (See <a class="local">'Quantitative (diagnostic)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– The gestational age of proteinuria onset can help establish the diagnosis of preeclampsia versus kidney disease. (See <a class="local">'Differential diagnosis of proteinuria'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Proteinuria documented before 20 weeks of gestation suggests preexisting kidney disease. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Proteinuria beginning after 20 weeks gestation is usually due to preeclampsia  (<a class="graphic graphic_table graphicRef79977" href="/z/d/graphic/79977.html" rel="external">table 1</a>), especially when associated with new or worsening hypertension or features of severe preeclampsia  (<a class="graphic graphic_table graphicRef76975" href="/z/d/graphic/76975.html" rel="external">table 3</a>). If hypertension is absent, then primary or secondary kidney disease should be considered. Preeclampsia is the most common cause of de novo nephrotic-range proteinuria in pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nephrotic syndrome</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In nephrotic syndrome, severe leg edema can be managed with sodium restriction, graduated compression stockings, and leg elevation. If edema persists despite these measures, loop diuretics may be used with caution. (See <a class="local">'Management of nephrotic syndrome in pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nephrotic syndrome is associated with an increased risk of deep venous thrombosis (DVT). Patients with severe nephrotic syndrome and very low serum albumin levels who are not at high risk for bleeding may benefit from prophylactic anticoagulation. (See  <a class="medical medical_review" href="/z/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome", section on 'Pregnant patients'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bile acid sequestrants and fibrates can be safely used in pregnancy to treat severe hyperlipidemia due to nephrotic syndrome; statins should be avoided. (See <a class="local">'Management of nephrotic syndrome in pregnancy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sibai BM, Lindheimer M, Hauth J, et al. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998; 339:667.</a></li><li><a class="nounderline abstract_t">Ros HS, Cnattingius S, Lipworth L. Comparison of risk factors for preeclampsia and gestational hypertension in a population-based cohort study. Am J Epidemiol 1998; 147:1062.</a></li><li><a class="nounderline abstract_t">Higby K, Suiter CR, Phelps JY, et al. Normal values of urinary albumin and total protein excretion during pregnancy. Am J Obstet Gynecol 1994; 171:984.</a></li><li><a class="nounderline abstract_t">Aziz MM, Kulkarni A, Shah L, et al. Physiologic proteinuria in labor and postpartum: The results of the postpartum proteinuria trial (PoPPy). Pregnancy Hypertens 2018; 13:22.</a></li><li><a class="nounderline abstract_t">Smith NA, Lyons JG, McElrath TF. Protein:creatinine ratio in uncomplicated twin pregnancy. Am J Obstet Gynecol 2010; 203:381.e1.</a></li><li><a class="nounderline abstract_t">Osmundson SS, Lafayette RA, Bowen RA, et al. Maternal proteinuria in twin compared with singleton pregnancies. Obstet Gynecol 2014; 124:332.</a></li><li><a class="nounderline abstract_t">Viberti GC, Jarrett RJ, Keen H. Microalbuminuria as prediction of nephropathy in diabetics. Lancet 1982; 2:611.</a></li><li><a class="nounderline abstract_t">Roberts M, Lindheimer MD, Davison JM. Altered glomerular permselectivity to neutral dextrans and heteroporous membrane modeling in human pregnancy. Am J Physiol 1996; 270:F338.</a></li><li><a class="nounderline abstract_t">Waugh JJ, Clark TJ, Divakaran TG, et al. Accuracy of urinalysis dipstick techniques in predicting significant proteinuria in pregnancy. Obstet Gynecol 2004; 103:769.</a></li><li><a class="nounderline abstract_t">Baba Y, Yamada T, Obata-Yasuoka M, et al. Urinary protein-to-creatinine ratio in pregnant women after dipstick testing: prospective observational study. BMC Pregnancy Childbirth 2015; 15:331.</a></li><li><a class="nounderline abstract_t">Baba Y, Furuta I, Zhai T, et al. Effect of urine creatinine level during pregnancy on dipstick test. J Obstet Gynaecol Res 2017; 43:967.</a></li><li><a class="nounderline abstract_t">Henderson JT, Thompson JH, Burda BU, Cantor A. Preeclampsia Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2017; 317:1668.</a></li><li><a class="nounderline abstract_t">Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol 2020; 135:e237. Reaffirmed 2023.</a></li><li><a class="nounderline abstract_t">Côté AM, Firoz T, Mattman A, et al. The 24-hour urine collection: gold standard or historical practice? Am J Obstet Gynecol 2008; 199:625.e1.</a></li><li><a class="nounderline abstract_t">Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003; 42:617.</a></li><li><a class="nounderline abstract_t">Geneen LJ, Webster KE, Reeves T, et al. Protein-creatinine ratio and albumin-creatinine ratio for the diagnosis of significant proteinuria in pregnant women with hypertension: Systematic review and meta-analysis of diagnostic test accuracy. Pregnancy Hypertens 2021; 25:196.</a></li><li><a class="nounderline abstract_t">Hirshberg A, Draper J, Curley C, et al. A random protein-creatinine ratio accurately predicts baseline proteinuria in early pregnancy. J Matern Fetal Neonatal Med 2014; 27:1834.</a></li><li><a class="nounderline abstract_t">Kyle PM, Fielder JN, Pullar B, et al. Comparison of methods to identify significant proteinuria in pregnancy in the outpatient setting. BJOG 2008; 115:523.</a></li><li><a class="nounderline abstract_t">Wilkinson C, Lappin D, Vellinga A, et al. Spot urinary protein analysis for excluding significant proteinuria in pregnancy. J Obstet Gynaecol 2013; 33:24.</a></li><li><a class="nounderline abstract_t">Nisell H, Trygg M, Bäck R. Urine albumin/creatinine ratio for the assessment of albuminuria in pregnancy hypertension. Acta Obstet Gynecol Scand 2006; 85:1327.</a></li><li><a class="nounderline abstract_t">Gangaram R, Naicker M, Moodley J. Comparison of pregnancy outcomes in women with hypertensive disorders of pregnancy using 24-hour urinary protein and urinary microalbumin to creatinine ratio. Int J Gynaecol Obstet 2009; 107:19.</a></li><li><a class="nounderline abstract_t">Baweja S, Kent A, Masterson R, et al. Prediction of pre-eclampsia in early pregnancy by estimating the spot urinary albumin: creatinine ratio using high-performance liquid chromatography. BJOG 2011; 118:1126.</a></li><li><a class="nounderline abstract_t">Cade TJ, de Crespigny PC, Nguyen T, et al. Should the spot albumin-to-creatinine ratio replace the spot protein-to-creatinine ratio as the primary screening tool for proteinuria in pregnancy? Pregnancy Hypertens 2015; 5:298.</a></li><li><a class="nounderline abstract_t">Khazardoost S, Maryamnoorzadeh, Abdollahi A, Shafaat M. Comparison of 8-h urine protein and random urinary protein-to-creatinine ratio with 24-h urine protein in pregnancy. J Matern Fetal Neonatal Med 2012; 25:138.</a></li><li><a class="nounderline abstract_t">Stout MJ, Conner SN, Colditz GA, et al. The Utility of 12-Hour Urine Collection for the Diagnosis of Preeclampsia: A Systematic Review and Meta-analysis. Obstet Gynecol 2015; 126:731.</a></li><li><a class="nounderline abstract_t">Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:753.</a></li><li><a class="nounderline abstract_t">Ekiz A, Kaya B, Polat I, et al. The outcome of pregnancy with new onset proteinuria without hypertension: retrospective observational study. J Matern Fetal Neonatal Med 2016; 29:1765.</a></li><li><a class="nounderline abstract_t">Yamada T, Obata-Yasuoka M, Hamada H, et al. Isolated gestational proteinuria preceding the diagnosis of preeclampsia - an observational study. Acta Obstet Gynecol Scand 2016; 95:1048.</a></li><li><a class="nounderline abstract_t">Tzur Y, Rimon E, Geva G, et al. Progression from isolated gestational proteinuria to preeclampsia with severe features. Acta Obstet Gynecol Scand 2021; 100:1620.</a></li><li><a class="nounderline abstract_t">Sarno L, Maruotti GM, Saccone G, et al. Pregnancy outcome in proteinuria-onset and hypertension-onset preeclampsia. Hypertens Pregnancy 2015; 34:284.</a></li><li><a class="nounderline abstract_t">Rezk M, Abo-Elnasr M, Al Halaby A, et al. Maternal and fetal outcome in women with gestational hypertension in comparison to gestational proteinuria: A 3-year observational study. Hypertens Pregnancy 2016; 35:181.</a></li><li><a class="nounderline abstract_t">Lindheimer MD, Kanter D. Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach. Obstet Gynecol 2010; 115:365.</a></li><li><a class="nounderline abstract_t">von Dadelszen P, Payne B, Li J, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 2011; 377:219.</a></li><li><a class="nounderline abstract_t">Payne B, Magee LA, Côté AM, et al. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can 2011; 33:588.</a></li><li><a class="nounderline abstract_t">van der Tuuk K, Holswilder-Olde Scholtenhuis MA, Koopmans CM, et al. Prediction of neonatal outcome in women with gestational hypertension or mild preeclampsia after 36 weeks of gestation. J Matern Fetal Neonatal Med 2015; 28:783.</a></li><li><a class="nounderline abstract_t">Tochio A, Obata S, Saigusa Y, et al. Does pre-eclampsia without proteinuria lead to different pregnancy outcomes than pre-eclampsia with proteinuria? J Obstet Gynaecol Res 2019; 45:1576.</a></li><li><a class="nounderline abstract_t">Dong X, Gou W, Li C, et al. Proteinuria in preeclampsia: Not essential to diagnosis but related to disease severity and fetal outcomes. Pregnancy Hypertens 2017; 8:60.</a></li><li><a class="nounderline abstract_t">Kim MJ, Kim YN, Jung EJ, et al. Is massive proteinuria associated with maternal and fetal morbidities in preeclampsia? Obstet Gynecol Sci 2017; 60:260.</a></li><li><a class="nounderline abstract_t">Thornton CE, Makris A, Ogle RF, et al. Role of proteinuria in defining pre-eclampsia: clinical outcomes for women and babies. Clin Exp Pharmacol Physiol 2010; 37:466.</a></li><li><a class="nounderline abstract_t">Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990; 163:1049.</a></li><li><a class="nounderline abstract_t">Piccoli GB, Attini R, Parisi S, et al. Excessive urinary tract dilatation and proteinuria in pregnancy: a common and overlooked association? BMC Nephrol 2013; 14:52.</a></li><li><a class="nounderline abstract_t">Cerdeira AS, Agrawal S, Staff AC, et al. Angiogenic factors: potential to change clinical practice in pre-eclampsia? BJOG 2018; 125:1389.</a></li><li><a class="nounderline abstract_t">Agrawal S, Cerdeira AS, Redman C, Vatish M. Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia: The SaPPPhirE Study. Hypertension 2018; 71:306.</a></li><li><a class="nounderline abstract_t">Sunderji S, Gaziano E, Wothe D, et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010; 202:40.e1.</a></li><li><a class="nounderline abstract_t">Hadker N, Garg S, Costanzo C, et al. Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective. J Med Econ 2010; 13:728.</a></li><li><a class="nounderline abstract_t">Moore AG, Young H, Keller JM, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med 2012; 25:2651.</a></li><li><a class="nounderline abstract_t">Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125:911.</a></li><li><a class="nounderline abstract_t">Rana S, Salahuddin S, Mueller A, et al. Angiogenic biomarkers in triage and risk for preeclampsia with severe features. Pregnancy Hypertens 2018; 13:100.</a></li><li><a class="nounderline abstract_t">Rolfo A, Attini R, Nuzzo AM, et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int 2013; 83:177.</a></li><li><a class="nounderline abstract_t">Chua S, Redman CW. Prognosis for pre-eclampsia complicated by 5 g or more of proteinuria in 24 hours. Eur J Obstet Gynecol Reprod Biol 1992; 43:9.</a></li><li><a class="nounderline abstract_t">Berks D, Steegers EA, Molas M, Visser W. Resolution of hypertension and proteinuria after preeclampsia. Obstet Gynecol 2009; 114:1307.</a></li><li><a class="nounderline abstract_t">Morton A, Burke M, Jarvis E, Kumar S. Changes in proteinuria and diagnosing preeclampsia in CKD pregnancy. Pregnancy Hypertens 2020; 20:92.</a></li><li><a class="nounderline abstract_t">Katz AI, Davison JM, Hayslett JP, et al. Pregnancy in women with kidney disease. Kidney Int 1980; 18:192.</a></li><li><a class="nounderline abstract_t">Reece EA, Coustan DR, Hayslett JP, et al. Diabetic nephropathy: pregnancy performance and fetomaternal outcome. Am J Obstet Gynecol 1988; 159:56.</a></li><li><a class="nounderline abstract_t">Bramham K, Seed PT, Lightstone L, et al. Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease. Kidney Int 2016; 89:874.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Schwotzer N, Cabiddu G, et al. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management. Kidney Int 2023; 103:264.</a></li><li><a class="nounderline abstract_t">Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. Obstet Gynecol 2009; 114:1326.</a></li><li><a class="nounderline abstract_t">Brown RA, Kemp GJ, Walkinshaw SA, Howse M. Pregnancies complicated by preeclampsia and non-preeclampsia-related nephrotic range proteinuria. Obstet Med 2013; 6:159.</a></li><li><a class="nounderline abstract_t">De Castro I, Easterling TR, Bansal N, Jefferson JA. Nephrotic syndrome in pregnancy poses risks with both maternal and fetal complications. Kidney Int 2017; 91:1464.</a></li><li><a class="nounderline abstract_t">Piccoli GB, Daidola G, Attini R, et al. Kidney biopsy in pregnancy: evidence for counselling? A systematic narrative review. BJOG 2013; 120:412.</a></li><li><a class="nounderline abstract_t">Holden F, Bramham K, Clark K. Rituximab for the maintenance of minimal change nephropathy - A report of two pregnancies. Obstet Med 2020; 13:145.</a></li><li><a class="nounderline abstract_t">Nara M, Kaga H, Saito M, et al. Successful Pregnancies in a Patient with Childhood-onset Steroid-dependent Nephrotic Syndrome during Rituximab Maintenance Therapy. Intern Med 2021; 60:2985.</a></li><li><a class="nounderline abstract_t">Collins R, Yusuf S, Peto R. Overview of randomised trials of diuretics in pregnancy. Br Med J (Clin Res Ed) 1985; 290:17.</a></li></ol></div><div id="topicVersionRevision">Topic 4808 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9725924" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9620050" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Comparison of risk factors for preeclampsia and gestational hypertension in a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7943114" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Normal values of urinary albumin and total protein excretion during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30177056" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Physiologic proteinuria in labor and postpartum: The results of the postpartum proteinuria trial (PoPPy).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20691965" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Protein:creatinine ratio in uncomplicated twin pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25004349" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Maternal proteinuria in twin compared with singleton pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6125757" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Microalbuminuria as prediction of nephropathy in diabetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8779896" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Altered glomerular permselectivity to neutral dextrans and heteroporous membrane modeling in human pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15051572" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Accuracy of urinalysis dipstick techniques in predicting significant proteinuria in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26667089" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Urinary protein-to-creatinine ratio in pregnant women after dipstick testing: prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28422372" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of urine creatinine level during pregnancy on dipstick test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28444285" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Preeclampsia Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32443079" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18718568" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The 24-hour urine collection: gold standard or historical practice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520612" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34237632" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Protein-creatinine ratio and albumin-creatinine ratio for the diagnosis of significant proteinuria in pregnant women with hypertension: Systematic review and meta-analysis of diagnostic test accuracy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24660896" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A random protein-creatinine ratio accurately predicts baseline proteinuria in early pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18201282" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of methods to identify significant proteinuria in pregnancy in the outpatient setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23259873" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Spot urinary protein analysis for excluding significant proteinuria in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17091412" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Urine albumin/creatinine ratio for the assessment of albuminuria in pregnancy hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19666171" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparison of pregnancy outcomes in women with hypertensive disorders of pregnancy using 24-hour urinary protein and urinary microalbumin to creatinine ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21481153" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prediction of pre-eclampsia in early pregnancy by estimating the spot urinary albumin: creatinine ratio using high-performance liquid chromatography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26597744" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Should the spot albumin-to-creatinine ratio replace the spot protein-to-creatinine ratio as the primary screening tool for proteinuria in pregnancy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21689049" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of 8-h urine protein and random urinary protein-to-creatinine ratio with 24-h urine protein in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26348193" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The Utility of 12-Hour Urine Collection for the Diagnosis of Preeclampsia: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34556300" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26135772" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The outcome of pregnancy with new onset proteinuria without hypertension: retrospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27109750" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Isolated gestational proteinuria preceding the diagnosis of preeclampsia - an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34043807" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Progression from isolated gestational proteinuria to preeclampsia with severe features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25799185" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pregnancy outcome in proteinuria-onset and hypertension-onset preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26909553" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Maternal and fetal outcome in women with gestational hypertension in comparison to gestational proteinuria: A 3-year observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20093912" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21185591" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21846448" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : PIERS proteinuria: relationship with adverse maternal and perinatal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24949930" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prediction of neonatal outcome in women with gestational hypertension or mild preeclampsia after 36 weeks of gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31257699" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Does pre-eclampsia without proteinuria lead to different pregnancy outcomes than pre-eclampsia with proteinuria?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28501282" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Proteinuria in preeclampsia: Not essential to diagnosis but related to disease severity and fetal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28534011" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Is massive proteinuria associated with maternal and fetal morbidities in preeclampsia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19930427" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Role of proteinuria in defining pre-eclampsia: clinical outcomes for women and babies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2403130" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23446427" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Excessive urinary tract dilatation and proteinuria in pregnancy: a common and overlooked association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29193681" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Angiogenic factors: potential to change clinical practice in pre-eclampsia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29229743" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia: The SaPPPhirE Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762001" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21138338" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22861812" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22261192" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30177034" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Angiogenic biomarkers in triage and risk for preeclampsia with severe features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23014459" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1737613" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prognosis for pre-eclampsia complicated by 5 g or more of proteinuria in 24 hours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19935034" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Resolution of hypertension and proteinuria after preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203727" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Changes in proteinuria and diagnosing preeclampsia in CKD pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7441987" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pregnancy in women with kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3394754" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Diabetic nephropathy: pregnancy performance and fetomaternal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26924064" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36481180" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Glomerular diseases in pregnancy: pragmatic recommendations for clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19935037" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pregnancy and laboratory studies: a reference table for clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27656249" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pregnancies complicated by preeclampsia and non-preeclampsia-related nephrotic range proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28233609" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Nephrotic syndrome in pregnancy poses risks with both maternal and fetal complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23320849" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Kidney biopsy in pregnancy: evidence for counselling? A systematic narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33093868" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Rituximab for the maintenance of minimal change nephropathy - A report of two pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33776000" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Successful Pregnancies in a Patient with Childhood-onset Steroid-dependent Nephrotic Syndrome during Rituximab Maintenance Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3917318" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Overview of randomised trials of diuretics in pregnancy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
